Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

摘要: Colorectal cancer is the second most common malignancy among men and women in United States, 5-year survival rate remains poor despite recent advances chemotherapy targeted agents. The mainstay of therapy for advanced disease cytotoxic including 5-FU, irinotecan, oxaliplatin. USFDA approval introduction therapies, cetuximab panitumumab (monoclonal antibodies targeting epidermal growth factor receptor (EGFR)) bevacizumab antibody vascular epithelial (VEGF)), has improved median patients with metastatic colorectal to around 24 months. Clearly, better more efficacious drugs are needed, target-specific agents remain future treatment. On this front, rapid being made, which likely change management cancer. However, absence specific biomarkers use agents, subset population who will benefit from treatment, a major drawback. In paper, we review that phases 1 2 clinical development, specifically EGFR its subsequent downstream pathways.